Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | APEX1 | P27695 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23484536 | 0.82 | KDM4E (0.67) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| SCHEMBL11743203 | 0.78 | KDM4E (0.57) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| SCHEMBL26672809 | 0.77 | ADRA2A (0.70) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| Racepinephrine SCHEMBL9659988 | 0.75 | TDP1 (0.84) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| Epinephrine SCHEMBL9659298 | 0.75 | TDP1 (0.84) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| Epinephrine SCHEMBL9659993 | 0.75 | TDP1 (0.84) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| Epinephrine SCHEMBL7921664 | 0.75 | TDP1 (0.84) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| Racepinephrine SCHEMBL9659303 | 0.75 | TDP1 (0.84) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| Racepinephrine SCHEMBL7921668 | 0.75 | TDP1 (0.84) | KDM4ETDP1ADRB2HIF1AMEN1 | |
| SCHEMBL11670117 | 0.73 | KDM4E (0.64) | KDM4ETDP1ADRB2HIF1AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285326-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285326-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230100523-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-03-30 | — | — | US | disclosed |
| US-11337938-B2 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200206163-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2020-07-02 | — | — | US | disclosed |
| US-10624864-B2 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190151261-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2019-05-23 | — | — | US | disclosed |
| US-20190105288-A1 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20170189352-A1 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189352-A1 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170165206-A1 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170165206-A1 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL, INC. | 2017-06-15 | — | — | US | disclosed |
| WO-2016149028-A2 | EPINEPHRINE FORMULATIONS | PAR PHARMACEUTICAL, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-20160263059-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-09-15 | — | — | US | disclosed |
| US-20160263059-A1 | EPINEPHRINE FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2016-09-15 | — | — | US | disclosed |
| US-9295657-B1 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9295657-B1 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9119876-B1 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9119876-B1 | Epinephrine formulations | PAR PHARMACEUTICAL, INC. (US) | 2015-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105288-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-11337938-B2 | Epinephrine formulations | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20160263059-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20190151261-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20170165206-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20230285326-A1 | EPINEPHRINE FORMULATIONS | ADRA1B, ADRA2C, ADRB1 | KDM4E 3695/4885TDP1 2694/4885ADRB2 6/4885 |
| US-10624864-B2 | Epinephrine formulations | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20200206163-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20170189352-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
| US-20230100523-A1 | EPINEPHRINE FORMULATIONS | ADRA1A, ADRB1, ADRA2C | KDM4E 3328/4885TDP1 1290/4885ADRB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.